Introduction:Basic information about CAS 68475-42-3|Anagrelide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Anagrelide |
|---|
| CAS Number | 68475-42-3 | Molecular Weight | 256.088 |
|---|
| Density | 1.8±0.1 g/cm3 | Boiling Point | 376.5±52.0 °C at 760 mmHg |
|---|
| Molecular Formula | C10H7Cl2N3O | Melting Point | 280 °C |
|---|
| MSDS | / | Flash Point | 181.5±30.7 °C |
|---|
Names
| Name | anagrelide |
|---|
| Synonym | More Synonyms |
|---|
Anagrelide BiologicalActivity
| Description | Anagrelide, an inhibitor of phosphodiesterase type III (PDEIII) (IC50=36 nM), inhibits platelet production. Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide plays in the antithrombopoietic action. The platelet-lowering agent[1]. |
|---|
| Related Catalog | Research Areas >>CancerResearch Areas >>Cardiovascular DiseaseSignaling Pathways >>Metabolic Enzyme/Protease >>Phosphodiesterase (PDE) |
|---|
| Target | PDEIII[1] |
|---|
| In Vitro | Anagrelide potently inhibits the development of marrow megakaryocytes (IC50=26 nM)[1]. Anagrelide is a distinct pharmacological agent that inhibit bone marrow megakaryocytopoiesis. Anagrelide (0.05, 0.3, 1 µM) inhibits only megakaryocytic cell growth not non-megakaryocytic cells. Anagrelide shifts cell growth to the non-megakaryocytic compartment, an effect that suggested that it was devoid of cytotoxic activity[2]. Anagrelide induces a cytotoxic effect in the GIST882 cell line at a submicromolar concentration (IC50= 16 nM), but Anagrelide is only weakly active in the GIST48 cell line[3].Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro[3]. Cell Proliferation Assay[2] Cell Line: Megakaryocytic and non-megakaryocytic cells Concentration: 0.05, 0.3, 1 µM Incubation Time: 12-day Result: Inhibited only megakaryocytic cell growth at every concentration tested |
|---|
| In Vivo | Anagrelide is effective in a GIST xenograft mouse model with KIT exon 9 mutation that may pose a therapeutic challenge, as these GISTs require a high daily dose of Imatinib[3].Anagrelide inhibits GIST growth in patient-derived mouse xenograft models. Anagrelide has therapeutic value in the treatment of GIST.Anagrelide has antitumoral activity in GIST xenograft models[3]. Anagrelide (5 mg/kg/bid) inhibits or reduces tumor growth in GIST2B, GIST9, GIST882 model models[3]. Animal Model: Adult female athymic mice bearing GIST2B, GIST3, GIST9, GIST882 model[3] Dosage: 5 mg/kg/bid Administration: Treated with 5 mg/kg/bid or with the combination of Anagrelide and Imatinib (given at the same dose and schedule as the single agents); for 10 days Result: Inhibited or reduced tumor growth in three (GIST2B, GIST9, GIST882) of these four models. The most potent effect was observed in the GIST2B model that harbors a KIT exon 9 mutation leading to p.A502_Y503 duplication. Reduced the tumor volume 68% after 10 days of therapy in this model. |
|---|
| References | [1]. Guosu Wang, et al. Comparison of the biological activities of Anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005 Oct;146(3):324-32. [2]. Y Hong, et al. Comparison between Anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of Anagrelide for the megakaryocytic lineage. Leukemia. 2006 Jun;20(6):1117-22. [3]. Olli-Pekka Pulkka, et al. Anagrelide for Gastrointestinal Stromal Tumor. Clin Cancer Res. 2019 Mar 1;25(5):1676-1687. |
|---|
Chemical & Physical Properties
| Density | 1.8±0.1 g/cm3 |
|---|
| Boiling Point | 376.5±52.0 °C at 760 mmHg |
|---|
| Melting Point | 280 °C |
|---|
| Molecular Formula | C10H7Cl2N3O |
|---|
| Molecular Weight | 256.088 |
|---|
| Flash Point | 181.5±30.7 °C |
|---|
| Exact Mass | 254.996613 |
|---|
| PSA | 44.70000 |
|---|
| LogP | 1.96 |
|---|
| Vapour Pressure | 0.0±0.9 mmHg at 25°C |
|---|
| Index of Refraction | 1.791 |
|---|
| InChIKey | OTBXOEAOVRKTNQ-UHFFFAOYSA-N |
|---|
| SMILES | O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1 |
|---|
| Storage condition | 2-8°C |
|---|
| Water Solubility | slightly soluble |
|---|
Toxicological Information
CHEMICAL IDENTIFICATION - RTECS NUMBER :
- NJ5903150
- CHEMICAL NAME :
- Imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-
- CAS REGISTRY NUMBER :
- 68475-42-3
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 1
- MOLECULAR FORMULA :
- C10-H7-Cl2-N3-O
- MOLECULAR WEIGHT :
- 256.10
HEALTH HAZARD DATAACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Unreported
- SPECIES OBSERVED :
- Human
- DOSE/DURATION :
- 300 ug/kg/7D
- TOXIC EFFECTS :
- Behavioral - headache Gastrointestinal - other changes
- REFERENCE :
- PAACA3 Proceedings of the American Association for Cancer Research. (Waverly Press, 428 E. Preston St., Baltimore, MD 21202) V.1- 1954- Volume(issue)/page/year: 29,212,1988
|
Safety Information
| Safety Phrases | S3-S7 |
|---|
| RIDADR | 3163 |
|---|
| Hazard Class | 2.2 |
|---|
| HS Code | 2933990090 |
|---|
Customs
| HS Code | 2933990090 |
|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Synonyms
| [14C]-Anagrelide |
| BL 4162A |
| Anagrelide (INN/BAN) |
| 6,7-di-chloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3 H ]-one base |
| Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-5,10-dihydro- |
| Anagrelida |
| UNII-K9X45X0051 |
| 6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one |
| Anagrelide |
| 6,7-Dichloro-5,10-dihydroimidazo[2,1-b]quinazolin-2(3H)-one |
| Anagrelidum |
| 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one |
| Anagrelidum [INN-Latin] |
| Agrelin |
| MFCD00866794 |
| 6,7-dichloro-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one |
| 6,7-Dichloro-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one |
| Anagrelida [INN-Spanish] |